Increased thrombin generation and activity in patients with systemic lupus erythematosus and anticardiolipin antibodies: evidence for a prothrombotic state [see comments]

The objective of this study is to determine whether patients with systemic lupus erythematosus (SLE) and anticardiolipin antibodies (ACA) have biochemical evidence of an ongoing prothrombotic state. Using a cross-sectional analysis of a cohort design in an outpatient SLE clinic setting, 43 consecutive patients with SLE participated. Patients underwent clinical and laboratory evaluations on two separate occasions at least 3 months apart. As part of the clinical evaluation, the following were ascertained: (1) the ongoing use of warfarin therapy; (2) the presence of prior venous and arterial thromboembolic disease by history, critical review of objective tests, and examination for reflux in the deep veins of the legs as an indicator of venous thrombosis; and (3) disease-related activity by performing a lupus activity criteria count (LACC). As part of the laboratory evaluation, blood was taken on both occasions and assayed for prothrombin fragments (F1 + 2) and fibrinopeptide A (FPA), as indices of thrombin generation and activity, respectively, and ACA. For the analyses, patients were classified as ACA+ if the assay was abnormal on both occasions and ACA- if the assay was negative on both occasions or negative on one occasion and positive on the other. ACA+ patients had: (1) a significantly higher mean level of F1 + 2 (1.07 nmol/L) than ACA- patients (0.79 nmol/L; P = .02) and patients receiving warfarin (0.47 nmol/L; P = .009) and (2) a significantly higher mean level of FPA (1.01 nmol/L) than ACA- patients (0.45 nmol/L; P = .02). When patients with prior thromboembolism were excluded from the analysis, significant differences in the mean levels of F1 + 2 and FPA between ACA+ and ACA- patients were still seen, whereas when patients with prior thromboembolism and/or active disease were excluded from the analysis, a significant difference in the mean level of FPA and a nonsignificant trend in the mean level of F1 + 2 were seen. The results of this study support the hypothesis that the presence of ACA in SLE patients is associated with an ongoing prothrombotic state.

[1]  P. Mannucci,et al.  Markers of Procoagulant Imbalance in Patients with Inherited Thrombophilic Syndromes , 1992, Thrombosis and Haemostasis.

[2]  J. Denburg,et al.  The Relationship of Antiphospholipid Antibodies to Thromboembolic Disease in Systemic Lupus Erythematosus: A Cross-Sectional Study , 1991, Thrombosis and Haemostasis.

[3]  S. Santoro,et al.  Antiphospholipid antibodies: anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders. Prevalence and clinical significance. , 1990, Annals of internal medicine.

[4]  J. Sánchez-Guerrero,et al.  Antiphospholipid Antibodies and the Antiphospholipid Syndrome in Systemic Lupus Erythematosus A Prospective Analysis of 500 Consecutive Patients , 1989, Medicine.

[5]  J. Hirsh,et al.  Detection of previous proximal venous thrombosis with Doppler ultrasonography and photoplethysmography. , 1989, Archives of internal medicine.

[6]  J M Edwards,et al.  Long-term hemodynamic and clinical sequelae of lower extremity deep vein thrombosis. , 1986, Journal of vascular surgery.

[7]  K. Bauer,et al.  Elevated factor Xa activity in the blood of asymptomatic patients with congenital antithrombin deficiency. , 1985, The Journal of clinical investigation.

[8]  A. P. Ball,et al.  Generation of the combined prothrombin activation peptide (F1-2) during the clotting of blood and plasma. , 1977, The Journal of clinical investigation.

[9]  R. Canfield,et al.  Measurement of fibrinopeptide A in human blood. , 1974, The Journal of clinical investigation.